GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Andros Pharmaceuticals Co 6917.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

30.75

+3.19%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Andros Pharmaceuticals Co

Its shares trade on Taipei Exchange under the ticker 6917.TWO. It has been listed since 12 January 2023. In the fiscal year to 31 December 2025, it reported revenue of TWD 5.5m and a net loss of TWD 53.8m. At that date it held total assets of TWD 559.0m and shareholders' equity of TWD 515.7m.

Andros Pharmaceuticals Co., Ltd. manufactures microencapsulated drugs. The company is headquartered in Zhubei, Hsinchu. The company went IPO on 2023-01-12. The products are focused on topical drugs and are developed with a focus on pain-related indications. The firm is mainly engaged in the authorization of product technology transfer, as well as the manufacture and sales of niche generic drugs and high-end skin care products. Niche generic drugs and high-end skin care products include LALP Cream, which is used for anesthesia before minor skin surgery and laser treatment; iMinos Solution, which is used for the treatment of androgenetic alopecia; and deoxyribonucleic acid (DNA) repair enzyme liposome (LipoT4N5), which has anti-wrinkle, anti-sun and anti-aging effects. The products are mainly sold in Hong Kong and Taiwan.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
12 Jan 2023

Leadership

Pay as last reported

  • Bingquan ChenCorporate Governance Officer
  • Mingwen LiDirector
  • Yiguang LiDirector
  • Yumin ZhuoDirector
  • Ms. Dah-Tsyr ChangIndependent Director
  • Mr. Chung-Ming LiuIndependent Director
  • Qionghua RuanIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Microencapsulated drugs focus on pain-related indications for niche markets.
  • LALP Cream and iMinos Solution target specific medical needs in Hong Kong and Taiwan.
  • DNA repair enzyme liposome LipoT4N5 offers anti-aging benefits for high-end skincare.

Weaknesses

  • Limited product range to topical drugs and niche generics.
  • Reliance on Hong Kong and Taiwan for primary sales markets.
  • IPO on 12 January 2023 restricts market expansion timeline.

Opportunities

  • Expansion into new markets beyond Hong Kong and Taiwan.
  • Growing demand for anti-aging skincare products globally.
  • Increasing focus on pain management solutions in healthcare.

Threats

  • Competition from established pharmaceutical companies in Taiwan.
  • Regulatory challenges in expanding product approvals.
  • Economic downturns affecting consumer spending on skincare.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.